{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009953","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.834067+00:00","generated_at":"2026-06-15T00:54:49.855171+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortress Biotech Q1 GAAP net loss widens to $21.5M; dermatology revenue drops 41%","bullets":["GAAP net loss $21.5M ($0.21/sh) vs $15.8M ($0.18/sh) YoY; non-GAAP core loss $6.5M ($0.06/sh).","Total net revenue $12.4M (down 48% YoY); Journey Medical dermatology revenue $12.2M (vs $20.8M) on Targadox generic pressure.","Cash $154.9M at Mar 31 vs $181.0M at Dec 31; Feb 2023 registered direct offering raised ~$13.9M.","DFD-29 Phase 3 topline results expected June 2023; NDA for papulopustular rosacea planned H2 2023.","Cosibelimab PDUFA date Jan 3, 2024; CUTX-101 rolling NDA to complete by end 2023; dotinurad Phase 1 topline data Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009953","json":"https://secwatch.observer/filing/0001558370-23-009953.json","markdown":"https://secwatch.observer/filing/0001558370-23-009953.md","text":"https://secwatch.observer/filing/0001558370-23-009953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023009953/0001558370-23-009953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023009953/fbio-20230515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:54:49.855171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ed1aca739a6faef9c041ef358fc8369a6c28cf2","claim":"Fortress Biotech, Inc. reported financial results for for the quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Fortress Biotech, Inc. issued a press release to announce financial results and recent corporate highlights for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023009953/0001558370-23-009953-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}